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Prediction Models of Cognitive 
Trajectories in Patients with 
Nonamnestic Mild Cognitive 
Impairment
Jin San Lee1,2,3, Seong-Kyung Cho4, Hee Jin Kim1,2, Yeo Jin Kim5, Key-Chung Park3, 
Samuel N. Lockhart  6, Duk L. Na1,2,8, Changsoo Kim7 & Sang Won Seo1,2,8,9
To evaluate prediction models of cognitive trajectories in patients with nonamnestic mild cognitive 
impairment (naMCI) using group-based trajectory analysis, we evaluated 121 patients with naMCI who 
underwent at least their first three yearly assessments. Group-based trajectory models were used to 
classify cognitive trajectories based on Clinical Dementia Rating Sum of Boxes scores over four years 
in patients with naMCI. A total of 22 patients (18.2%) were classified into the “fast-decliners” group, 
while 99 patients (81.8%) were classified into the “slow-decliners” group. The mean age was higher 
in the fast-decliners than in the slow-decliners (p = 0.037). Compared to the slow-decliners, the fast-
decliners were more frequently impaired in the domains of language (p = 0.038) and frontal/executive 
functions (p = 0.042), and had more frequent multiple-domain cognitive impairment (p = 0.006) on 
baseline neuropsychological tests. The rate of conversion to dementia was significantly higher in the 
fast-decliners than in the slow-decliners (86.4% vs. 10.1%, p < 0.001). Our findings showed that there 
are indeed distinct patterns of cognitive trajectories in patients with naMCI. Close observation of naMCI 
patients’ baseline demographic and clinical profiles in clinical settings may help identify individuals at 
greatest risk for dementia.
Mild cognitive impairment (MCI) is a clinically heterogeneous syndrome, and the MCI syndrome can be clas-
sified into amnestic and nonamnestic MCI (naMCI) subtypes depending on the degree of impairment in the 
memory domain1. Patients with naMCI have impairments in other cognitive domains than memory (e.g. frontal/
executive, language, or visuospatial). Previous studies have shown that amnestic MCI patients have a high likeli-
hood of progressing to Alzheimer’s Disease (AD) dementia, whereas naMCI patients have a higher likelihood of 
progressing to a non-AD dementia2–5. In particular, the causes and outcomes of cognitive impairments in naMCI 
may be more heterogeneous6. However, to date, the long-term cognitive trajectories in patients with naMCI, 
assessed using clinical and functional measures, are not well known.
Many studies have examined the clinical and neuropsychological profiles related to the likelihood of pro-
gression from MCI to dementia. These previous reports have shown that older age, verbal memory impairment, 
frontal/executive dysfunction, multiple-domain impairment, and the presence of at least one apolipoprotein E 
(APOE) ε4 allele increase the risk of conversion to dementia7–12. However, most previous studies have evaluated 
clinical outcomes by comparing naMCI with amnestic MCI, or by combining naMCI and amnestic MCI patients 
together12–14. So far, there have been no studies investigating the clinical profiles related to disease progression 
of naMCI separately from amnestic MCI. Since the research criteria for MCI due to AD consider both amnestic 
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MCI and naMCI as possible prodromal stages of AD-type dementia, understanding the cognitive trajectories of 
naMCI has clinical importance15.
Group-based trajectory analysis provides a tool for figuratively painting a statistical portrait of the predictors 
and consequences of distinct trajectories of development16. It also can enable identification, summarization, and 
communication of complex patterns in longitudinal data17. Group-based models have been applied to address 
questions related to developmental trajectories in psychology18,19, medicine20, and criminology21. Several studies 
have also used these models to facilitate causal inference in situations where randomization to treatment condi-
tion is not possible22,23. Recently, a few studies have used trajectory analysis to identify predictive or prognostic 
factors in patients with MCI10,24,25. However, no studies have applied this method to naMCI patients to determine 
longitudinal cognitive trajectories.
To better understand the cognitive trajectories of naMCI, we evaluated 121 patients with naMCI who under-
went at least their first three yearly assessments. The primary goal was to classify longitudinal cognitive trajecto-
ries of naMCI using group-based trajectory analysis. The secondary goal was to evaluate the demographic and 
clinical risk factor profiles which best predicted the prognosis of naMCI patients. We hypothesized not only that 
group-based trajectory analysis would enable to identification of distinct groups of naMCI patients based on lon-
gitudinal trajectories of decline, but also that specific patient characteristics would predict membership in these 
naMCI trajectory groups.
Results
Demographic and clinical characteristics. The demographic and clinical characteristics of participants 
at baseline are presented in Table 1. The mean age of participants was 71.0 years and 87 (71.9%) were female. 
APOE genotyping was performed in 76 (62.8%) of 121 patients, and 14 were ε4 carriers (11.6% of all patients). 
The mean (standard deviation [SD]) Mini-Mental Status Examination (MMSE), Clinical Dementia Rating (CDR), 
and Clinical Dementia Rating Sum of Boxes (CDR-SB) scores at baseline were 26.2 (3.5), 0.5 (0.1), and 1.3 (0.9), 
respectively. The most frequently involved cognitive domain was frontal/executive function (45.5%), followed by 
language (43.8%) and visuospatial (25.6%) functions. A total of 28 (23.1%) patients were impaired in multiple 
cognitive domains; of these, five (17.9%) had three domains affected and 23 (82.1%) had two domains involved.
Groups identified by group-based trajectory analysis. In order to define the cognitive trajectories 
based on CDR-SB score in patients with naMCI, we tested solutions varying the number of groups from one to 
Total (N = 121)
Age, years 71.0 (7.3)
Female, N (%) 87 (71.9)
Education, years 9.0 (5.3)
Total follow-up, years 3.8 (0.8)
APOE4 carrier, N (%)* 14 (11.6)
Vascular risk factors
  Hypertension, N (%) 60 (49.6)
  Diabetes, N (%) 39 (32.2)
  Dyslipidemia, N (%) 32 (26.4)
  Cardiovascular disease, N (%) 21 (17.4)
  History of stroke, N (%) 11 (9.1)
GDepS 15.0 (8.4)
  Range 0–24
MMSE 26.2 (3.5)
  Range 22–30
CDR 0.5 (0.1)
  Range 0–0.5
CDR-SB 1.3 (0.9)
  Range 0–2.5
Involved cognitive domain
  Attention 28 (23.1)
  Language 53 (43.8)
  Visuospatial 31 (25.6)
  Frontal/executive 55 (45.5)
  Multiple-domain 28 (23.1)
Table 1. Demographic and clinical characteristics of the study participants. Values are mean (SD), score, 
or N (%). *APOE genotyping was performed in 76 (62.8%) of the 121 patients with naMCI. Abbreviations: 
N = number; SD = standard deviation; APOE4 = apolipoprotein E ε4; GDepS = Geriatric Depression Scale, 
MMSE = Mini-Mental State Examination; CDR = Clinical Dementia Rating; CDR-SB = Clinical Dementia 
Rating Scale Sum of Boxes.
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four. According to the Bayesian Information Criterion (BIC) value (−698.08), the two-group solution with a 
quadratic polynomial shape was found to be the most appropriate. The cognitive trajectories in 121 patients with 
naMCI are illustrated in Fig. 1. A total of 22 patients (18.2%) were classified into the “fast-decliners” group, while 
99 patients (81.8%) were classified into the “slow-decliners” group. The change in CDR-SB score over four years 
was greater than seven points in the fast-decliners, but less than one point in the slow-decliners.
Identifying variables that distinguish trajectories. Table 2 presents the results of comparisons of 
demographic and clinical characteristics between the fast- and slow-decliners. The mean age was higher in the 
fast-decliners than in the slow-decliners (74.0 ± 6.7 vs. 70.4 ± 7.3, p = 0.037). There were no differences in the 
ratios of gender and years of education between the fast- and slow-decliners. In the fast-decliners, the cogni-
tive and functional impairment evaluated by the CDR-SB at baseline was significantly greater than that of the 
slow-decliners (2.1 ± 0.8 vs. 1.1 ± 0.7, p < 0.001). In addition, we compared the proportion of participants with 
abnormal results on baseline neuropsychological tests between the two groups. Compared to the slow-decliners, 
the fast-decliners were impaired more frequently in the domains of language (p = 0.038) and frontal/executive 
functions (p = 0.042), and had more frequent multiple-domain cognitive impairment (p = 0.006, Fig. 2). In addi-
tion, logistic regression analysis controlling for age and the number of impaired cognitive domains confirmed 
that impaired language (OR 7.7, p = 0.046) and frontal/executive functions (OR 8.2, p = 0.040) significantly pre-
dicted membership in the fast-decliners group.
Longitudinal changes in neuropsychological test performance over time by group-based tra-
jectories. Table 3 shows mixed effects models examining how worsening in performance on neuropsycho-
logical tests over time was related to naMCI patient group status, defined by the group-based trajectory method. 
Significant group-by-time interactions were obtained for most neuropsychological tests from baseline to year 
five. Over time, the fast-decliners showed significantly worse performance than the slow-decliners in the Korean 
version of the Boston Naming Test (K-BNT), the Seoul Verbal Learning Test (SVLT), the Rey-Osterrieth Complex 
Figure Test (RCFT), the Controlled Oral Word Association Test (COWAT, animal), MMSE, CDR, and CDR-SB 
scores. As shown in Table 2, the rate of conversion to dementia was significantly higher in the fast-decliners 
(86.4%) than in the slow-decliners (10.1%).
Discussion
We assessed longitudinal cognitive trajectories in a sample of 121 patients with naMCI using group-based trajec-
tory analysis based on CDR-SB scores. The results from the present study showed that there are indeed distinct 
patterns of cognitive trajectories in patients with naMCI: one group can be classified as fast-decliners, while the 
remaining participants can be classified as slow-decliners. Furthermore, we found that several baseline demo-
graphic and clinical characteristics, including older age and impairments in the cognitive domains of language 
and frontal/executive functions, are risk factors for predicting future decline among naMCI patients. Given 
the increasing interest in the clinical outcomes of naMCI, our results suggest that close observation of naMCI 
patients’ baseline demographic and clinical profiles may help identify individuals at greatest risk for dementia.
The novelty of the present study is that it takes into account the variability of cognitive trajectories based on 
CDR-SB in individual patients, and thereby seeks to refine our understanding of the relationship between disease 
progression and prognosis. We found that the trajectory groups derived from our group-based trajectory mod-
eling were a convenient statistical device for understanding cognitive trajectories in patients with naMCI. The 
fast-decliners, representing less than 20% of the study participants, showed continuous deterioration in CDR-SB 
scores over time, while the slow-decliners showed no change. To date, only a few studies have investigated lon-
gitudinal performance in patients with naMCI26. However, these previous studies operationally defined clinical 
Figure 1. Cognitive trajectories based on CDR-SB score from baseline (year 0) to year 4 among 121 patients 
with naMCI. Shown are results of the group-based trajectory analysis used to identify groups of patients 
following a similar trajectory of cognitive decline over time, as assessed with the CDR-SB score at years 0, 1, 2, 
3, and 4. The 2 cognitive trajectories that were identified are shown with 95% confidence intervals (red or blue 
shaded area). CDR-SB = Clinical Dementia Rating Scale Sum of Boxes; naMCI = nonamnestic mild cognitive 
impairment.
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progression as a worsening on the CDR-SB over two years. In contrast, the trajectory analysis performed in the 
present study was designed to identify clusters of individuals who have followed a similar developmental trajec-
tory on an outcome of interest17,27,28. To the best of our knowledge, this is the first study to conduct a data-driven 
classification of naMCI patients based on longitudinal performance, rather than a longitudinal analysis based on 
a priori classification.
Another noteworthy finding was that there were distinct baseline demographic and clinical profiles able to 
predict the prognosis of patients with naMCI. At baseline evaluation, the fast-decliners were older, had more 
frequent impairments in the domains of language and frontal/executive functions, and had more frequent 
multiple-domain involvement on neuropsychological testing compared to the slow-decliners. Our finding is 
partly consistent with a previous study, which showed that naMCI patients who clinically progressed were older 
and had lower baseline performance on category fluency and visuospatial tasks compared with naMCI patients 
who remained stable26. That study sample, however, consisted of single-domain (frontal/executive dysfunction) 
naMCI patients. Notably, we found baseline impairments in both language and frontal/executive functions in 
Fast-decliners 
(N = 22)
Slow-decliners 
(N = 99) P-value
Age, years 74.0 (6.7) 70.4 (7.3) 0.037
Female, N (%) 18 (81.8) 69 (69.7) 0.253
Education, years 7.7 (5.8) 9.3 (5.2) 0.205
Total follow-up, years 3.5 (0.7) 3.9 (1.4) 0.049
APOE4 carrier, N (%) 3 (13.6) 11 (11.1) 0.634
Vascular risk factors
  Hypertension, N (%) 13 (59.1) 47 (47.5) 0.324
  Diabetes, N (%) 10 (45.5) 29 (29.3) 0.142
  Dyslipidemia, N (%) 4 (18.2) 28 (28.3) 0.331
  Cardiovascular disease, N (%) 2 (9.1) 19 (19.2) 0.258
  History of stroke, N (%) 1 (4.5) 10 (10.1) 0.412
GDepS 16.2 (8.1) 14.8 (8.5) 0.482
CDR-SB 2.1 (0.8) 1.1 (0.7) <0.001
Conversion to dementia 19 (86.4) 10 (10.1) <0.001
  AD 14 (73.7) 6 (60.0)
  DLB 2 (10.5) 3 (30.0)
  SVaD 2 (10.5) 1 (10.0)
  CBS 1 (5.3) 0 (0.0)
Table 2. Comparisons of demographics, baseline neuropsychological test performances, and dementia 
conversion between the fast- and slow-decliners in patients with naMCI. Values are mean (SD) or number 
(%). Chi-square and Student’s t-tests were performed to compare demographic variables between the fast- 
and slow-decliners groups. Abbreviations: N = number; SD = standard deviation; APOE4 = apolipoprotein 
E ε4; GDepS = Geriatric Depression Scale, MMSE = Mini-Mental State Examination; CDR = Clinical 
Dementia Rating; CDR-SB = Clinical Dementia Rating Scale Sum of Boxes; K-BNT = Korean version of 
the Boston Naming Test; RCFT = Rey-Osterrieth Complex Figure Test; SVLT = Seoul Verbal Learning Test; 
COWAT = Controlled Oral Word Association Test; AD = Alzheimer’s disease; DLB = dementia with Lewy 
bodies; SVaD = subcortical vascular dementia; CBS = corticobasal syndrome.
Figure 2. Comparisons between proportions of naMCI patients in the fast-decliners (red) and slow-decliners 
(blue) groups with abnormal baseline neuropsychological test results. naMCI = nonamnestic mild cognitive 
impairment. *p < 0.05.
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patients with naMCI strongly predicted membership in the fast-decliners group, even after controlling for age and 
the number of involved cognitive domains. Our results therefore suggest that investigating baseline clinical pro-
files in patients with naMCI has important implications for identifying individuals who are at risk for dementia.
In the present study, mixed effects models also demonstrated that the fast-decliners group exhibited wors-
ening in neuropsychological test performance over time, including worsening in the memory domain. Indeed, 
patients with naMCI in our study mainly converted to clinically diagnosed AD dementia. Our findings are not in 
line with some previous studies showing that naMCI patients have a higher likelihood of progressing to a non-AD 
dementia2–5. This discrepancy could be explained by factors including differences between clinical and patholog-
ical diagnosis, a relatively small sample size, or insufficient follow-up. Indeed, several other studies have shown 
that a substantial number of naMCI patients progress to AD dementia during follow-up29,30.
Several limitations of the present study should be acknowledged. First, as the number of patients in the 
fast-decliners group was relatively small, the analyses may have had low statistical power. However, considering 
the prevalence of naMCI in community-based studies (0.5–6%)13,31,32, the results of our study still have clinical 
significance. Further investigation with larger sample sizes and a longer follow-up period is needed to understand 
long-term trajectory of naMCI. Second, it is not a population-based study, which limits its generalizability to 
the general population. Third, we did not have molecular imaging or neuropathologic data on the participants. 
Fourth, there could be a large number of situations where a common pattern of change over time cannot be 
assumed. Fifth, although we followed naMCI patients for a minimum of three years, this may not have been a 
sufficient length of time to properly evaluate the likelihood of conversion to dementia. Finally, some of the par-
ticipants in this study had somewhat high Geriatric Depression Scale (GDepS) or low MMSE scores. However, 
depression is common in individuals with MCI33,34 and the naMCI patients with high GDepS score in this study 
did not meet the diagnostic criteria for major depressive disorder on baseline screening. Also, many elderly peo-
ple in South Korea have low educational levels due to the Korean War, thus, the MMSE scores of the elderly who 
have normal cognitive function are relatively lower than those of other countries. We excluded participants who 
met criteria for dementia based on the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)35, 
not on the MMSE score.
In conclusion, our findings showed that there are indeed distinct patterns of cognitive trajectories in patients 
with naMCI. We suggest that evaluating baseline clinical profiles as risk factors for cognitive deterioration may 
help inform early-life interventions in patients with naMCI. Close observation of naMCI patients’ baseline demo-
graphic and clinical profiles in clinical settings may help identify individuals at greatest risk for dementia.
Group by time
Fast-decliners vs. Slow-decliners
Estimate SE p-value
Neuropsychological tests
  Digit span: Forward −0.21 0.09 0.015
  Digit span: Backward −0.10 0.12 0.368
  K-BNT −0.72 0.18 <0.001
  RCFT: Copy −0.51 0.18 0.005
  SVLT: Immediate recall −0.38 0.11 0.001
  SVLT: Delayed recall −0.48 0.14 0.001
  SVLT: Recognition score −0.34 0.12 0.007
  RCFT: Immediate recall −0.37 0.09 <0.001
  RCFT: Delayed recall −0.30 0.09 0.001
  RCFT: Recognition score −0.55 0.18 0.003
  Stroop color reading −0.20 0.12 0.109
  COWAT: Animal −0.29 0.09 0.001
  COWAT: Supermarket −0.21 0.11 0.056
  COWAT: Phonemic total −0.11 0.10 0.305
MMSE −0.91 0.18 <0.001
CDR 0.19 0.02 <0.001
CDR-SB 1.53 0.12 <0.001
Table 3. Mixed effects models of worsening in performance on neuropsychological tests over time by group-
based trajectories in patients with naMCI. Linear mixed effects model were performed using group (fast-
decliners vs. slow-decliners), time, and the interaction term between group and time (group by time) as fixed 
effects and patient as a random effect. Age-, sex-, and education-specific z-scores were used in the comparison 
of longitudinal neuropsychological performance between the fast- and slow-decliners groups. Abbreviations: 
naMCI = non-amnestic mild cognitive impairment; SE = standard error; K-BNT = Korean version of the 
Boston Naming Test; RCFT = Rey-Osterrieth Complex Figure Test; SVLT = Seoul Verbal Learning Test; 
COWAT = Controlled Oral Word Association Test; MMSE = mini-mental state examination; CDR = Clinical 
Dementia Rating; CDR-SB = Clinical Dementia Rating sum of boxes.
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Methods
Participants. The study participants were included from two registry studies: 54 patients with naMCI from 
the Memory Disorder Clinic in Samsung Medical Center (May 2003 to June 2015) and 67 patients with naMCI 
from the Clinical Research Center for Dementia of South Korea study, a nationwide multicenter cohort study of 
cognitive disorders involving 31 memory disorder clinics at universities and general hospitals in South Korea 
(September 2005 to August 2012)36. These two studies used a common standardized diagnostic assessment, which 
included an assessment for the diagnostic criteria for naMCI. All participants met the clinical criteria proposed by 
Petersen1: cognitive complaints reported by patients or by their caregiver; scores lower than −1.0 SD of the age-, 
sex-, and education-adjusted norms on tests for at least one of the main cognitive domains except memory; gen-
erally intact activities of daily living; and the absence of dementia. They also had completed at least their first three 
yearly assessments, with the same interview and neuropsychological testing conducted at both their baseline and 
follow-up evaluations. The study participants were recruited according to the modified questionnaire of Health 
screening and random recruitment for cognitive aging research37.
Participants were excluded if they met criteria for dementia based on the DSM-IV; had a history of a neu-
rological disorder, current psychiatric illness, substance abuse, or head trauma with loss of consciousness; had 
uncontrolled diabetes or hypothyroidism; or were taking medications that affect cognition. Participants under-
went a brain magnetic resonance imaging scan and were excluded if they had a cerebral, cerebellar, or brainstem 
infarction; hemorrhage; brain tumor; hydrocephalus; severe cerebral white matter hyperintensities (deep white 
matter ≥2.5 cm and caps or band ≥1.0 cm); or severe head trauma.
Standard protocol approvals, registrations, and patient consents. We obtained written informed 
consent from each patient. This study was approved by the Institutional Review Board at the Samsung Medical 
Center. All methods were carried out in accordance with approved guidelines.
Neuropsychological testing and clinical assessments. All participants underwent neuropsycholog-
ical testing using a standardized neuropsychological battery, the Seoul Neuropsychological Screening Battery38. 
The battery contains tests for attention, language, praxis, elements of Gerstmann syndrome, visuoconstructive 
function, verbal and visual memory, and frontal/executive function. The battery in the present study includes 
Digit span (forward and backward), K-BNT, RCFT (copying, immediate and 20-minute delayed recall, and rec-
ognition), SVLT (3 learning-free recall trials of 12 words, a 20-minute delayed recall trial for these 12 items, and 
a recognition test), phonemic and semantic COWAT, and a Stroop Test (word and color reading of 112 items 
during a 2-minute period). Age-, sex- and education-specific norms for each test, based on 447 normal subjects, 
were used for comparison. Z-scores lower than −1.0 SD of the age-, sex- and education-adjusted norms were 
considered abnormal. We also performed MMSE, CDR, CDR-SB, and GDepS.
Conversion to dementia. The diagnosis of dementia was based on criteria from the DSM-IV and required 
clinical evidence of cognitive deficits confirmed by neuropsychological testing, as well as evidence of impairment 
in social or occupational functions confirmed by activities of daily living scales. The MMSE or CDR-SB scores 
were not used in the determination of the diagnosis of dementia. For the diagnosis of probable AD, we used the 
criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease 
and Related Disorders Association39. Established diagnostic criteria for clinical dementia with Lewy bodies, sub-
cortical vascular dementia, and corticobasal syndrome were also used40–42.
Statistical analyses. We used group-based trajectory models (SAS Proc Traj; SAS Institute Inc) to clas-
sify cognitive trajectories based on CDR-SB scores over four years in 121 patients with naMCI28. The model 
selection for the trajectory analysis was based on the BIC values between models28. The BIC enables a balance 
of both model complexity and model fit, in a manner similar to the adjusted R2, with lower numbers indicating 
a better model fit. The appropriate number of trajectories and trajectory shape were selected by recommended 
procedures19,28,43.
Continuous variables were presented as means ± SD and were compared using Student’s t-test. Categorical 
variables were compared using the Chi-square test or Fisher’s exact test. To investigate the effects of baseline neu-
ropsychological test abnormalities on cognitive trajectory group based on CDR-SB score, we performed a logis-
tic regression analysis after entering age (continuous), neuropsychological test abnormalities on each cognitive 
domain (three categories: language, visuospatial, frontal/executive functions), and single- or multiple-domain 
involved status as the independent variables, and group as the dependent variable. To determine whether there 
were significant differences in neuropsychological performance over time between the groups, we also performed 
linear mixed effects modeling using age, years of education, group, time, and the interaction term between group 
and time (group by time) as fixed effects, and patient as a random effect. Statistical significance was set at p < 0.05 
in two-tailed tests. Statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).
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